UCB Investor Relations Material
Latest events
H1 2025
UCB
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from UCB SA
Access all reports
UCB SA is a global biopharmaceutical company specializing in the discovery and development of innovative medicines and solutions for severe neurological and immunological disorders. The company's main areas of focus include treatments for conditions such as epilepsy, Parkinson's disease, and various immunological diseases. UCB operates through its biopharmaceutical segment, which develops, manufactures, and markets these therapies. The company is headquartered in Brussels, Belgium, and its shares are listed on the Euronext Brussels.
Key slides for UCB SA
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
UCB
Country
🇧🇪 Belgium